Dyne Therapeutics, Inc.
A clinical-stage biotechnology company developing medicines for inherited muscle diseases such as Duchenne muscular dystrophy and myotonic dystrophy. Its FORCE platform delivers RNA-based therapies directly to muscle tissue. Founded in 2017 and incubated by venture firm Atlas Venture, the company takes its name from the "dyne," a unit of force in physics — a fitting nod to its mission of restoring muscle strength.
Bought 1.71M · Sold 4.00M
Bought 934.6K · Sold 1.31M
Sold 510.2K
Granted 1.11M · Bought 934.6K · Sold 4.19M
Sold 46.5K
Granted 1.92M · Sold 1.39M
Granted 325.3K · Bought 132.0K · Sold 22.1K
Granted 335.2K · Sold 155.8K
Granted 180.5K · Sold 11.3K
Granted 156.2K · Sold 2.0K
Granted 140.8K · Sold 46.3K
Granted 347.8K · Sold 250.4K
Granted 339.2K · Sold 239.3K
Granted 451.6K · Sold 339.2K
Granted 131.1K · Sold 9.5K
Bought 16.0K
Granted 16.5K · Sold 16.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kersten DirkDirector · 88 transactions | — | 21.35M | — | 1.71M | 4.00M |
| Atlas Venture Associates Opportunity I, L.P. +8 co-filers10% owner · 25 transactions | — | 8.05Mas of Feb 2024 | — | 934.6K | 1.31M |
| Atlas Venture Associates XI, L.P. +2 co-filers10% owner · 5 transactions | — | 6.82Mas of Feb 2024 | — | — | 510.2K |
| Rhodes Jason PDirector · 100 transactions | — | 6.81M | 1.11M | 934.6K | 4.19M |
| Atlas Venture Associates Opportunity I, L.P. +5 co-filers10% owner · 2 transactions | — | 2.31Mas of Mar 2024 | — | — | 46.5K |
| Brumm Joshua TCEO & President, Director · 59 transactions | +410.7% | 546.6Kas of Mar 2024 | 1.92M | — | 1.39M |
| Cox JohnCEO & President, Director · 22 transactions | — | 440.2K | 325.3K | 132.0K | 22.1K |
| Beskrovnaya OxanaChief Scientific Officer · 41 transactions | +915.3% | 195.8Kas of Mar 2025 | 335.2K | — | 155.8K |
| Kerr DouglasChief Medical Officer · 11 transactions | — | 169.2K | 180.5K | — | 11.3K |
| Friedl-Naderer JohannaChief Commercial Officer · 11 transactions | — | 154.2K | 156.2K | — | 2.0K |
| Farwell WildonChief Medical Officer · 26 transactions | +187% | 143.5Kas of Aug 2024 | 140.8K | — | 46.3K |
| McNeill JonathanChief Business Officer · 49 transactions | +258.7% | 132.4Kas of Aug 2024 | 347.8K | — | 250.4K |
| High Susanna GattiChief Operating Officer · 38 transactions | +266.6% | 131.6Kas of Sep 2024 | 339.2K | — | 239.3K |
| Scalzo Richard WilliamSVP, Head of Finance & Admin. · 61 transactions | +967% | 122.3Kas of Mar 2025 | 451.6K | — | 339.2K |
| Lucera ErickChief Financial Officer · 5 transactions | — | 121.6K | 131.1K | — | 9.5K |
| Posner Brian SDirector · 7 transactions | — | 24.5K | — | 16.0K | — |
| Incerti CarloDirector · 2 transactions | — | 0as of Nov 2024 | 16.5K | — | 16.5K |
| Lubner David CharlesDirector · 1 transaction | -100% | 0 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -8.81M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.